Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy.
about
Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of DiseasesStress, seizures, and hypothalamic-pituitary-adrenal axis targets for the treatment of epilepsyIon transporters in brain tumorsThe potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategiesAge- and sex-dependent susceptibility to phenobarbital-resistant neonatal seizures: role of chloride co-transportersAcute TrkB inhibition rescues phenobarbital-resistant seizures in a mouse model of neonatal ischemiaLoop diuretics affect skeletal myoblast differentiation and exercise-induced muscle hypertrophy.Neuronal chloride accumulation and excitatory GABA underlie aggravation of neonatal epileptiform activities by phenobarbital.Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction.Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.Expression of GABA receptor subunits in the hippocampus and thalamus after experimental traumatic brain injuryBumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures.Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizuresSTE20/SPS1-related proline/alanine-rich kinase is involved in plasticity of GABA signaling function in a mouse model of acquired epilepsy.Is switching from brand name to generic formulations of phenobarbital associated with loss of antiepileptic efficacy?: a pharmacokinetic study with two oral formulations (Luminal(®) vet, Phenoleptil(®)) in dogs.Reactive astrogliosis causes the development of spontaneous seizures.Altered GABA signaling in early life epilepsies.Possible alterations in GABAA receptor signaling that underlie benzodiazepine-resistant seizures.Traumatic alterations in GABA signaling disrupt hippocampal network activity in the developing brain.Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.Limitations of Current GABA Agonists in Neonatal Seizures: Toward GABA Modulation Via the Targeting of Neuronal Cl(-) Transport.Sensitive isotope dilution liquid chromatography/tandem mass spectrometry method for quantitative analysis of bumetanide in serum and brain tissue.Astrocytic Acid-Sensing Ion Channel 1a Contributes to the Development of Chronic EpileptogenesisFinding a better drug for epilepsy: antiepileptogenesis targets.Seizure-induced disinhibition of the HPA axis increases seizure susceptibility.Possible role of GABAergic depolarization in neocortical neurons in generating hyperexcitatory behaviors during emergence from sevoflurane anesthesia in the ratPast and present definitions of epileptogenesis and its biomarkers.Is it safe to use a diuretic to treat seizures early in development ?The WNK-SPAK/OSR1 pathway: master regulator of cation-chloride cotransporters.Exploring novel AEDs from drugs used for treatment of non-epileptic disorders.Astroglial Scarring and Seizures: A Cell Biological Perspective on Epilepsy.Computational approaches for innovative antiepileptic drug discovery.Ion transporters in brain endothelial cells that contribute to formation of brain interstitial fluid.Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy.The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice.Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus.Compromised GABAergic inhibition contributes to tumor-associated epilepsy.Chronic stress shifts the GABA reversal potential in the hippocampus and increases seizure susceptibility.The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat.
P2860
Q26786331-17A74701-FC9B-4F77-8117-17A3572A0701Q27013911-EFEA5E45-0B97-4864-945F-645EAC5E2881Q28082580-E3AB1DBC-78D8-47A7-98A9-311E114AF63FQ30576758-797777A8-5EED-4061-BF14-A4DBD6447CB1Q30576762-77880879-7433-4A80-BF28-0D263E43A9A6Q30650230-B7306E93-7872-4DF8-AED0-4B8C2F41048FQ30699108-91CAAD19-8A03-494F-8F39-A0CA76797BE7Q33572473-333F49D8-6002-42FC-87FA-A30F525AA6D0Q34026277-5EAB9924-3107-459C-B184-B749B1846796Q34339959-EF82F843-DBF6-413F-8311-5D091DE27BA4Q34458158-3801106D-7828-4DC6-8618-D9E100A4D1EEQ34550987-A3CE079B-B002-46D2-8350-24FA83D7E1D8Q34638960-5F64B982-E802-4DF6-BD86-0D90DE90F8E5Q34823865-41F7DD31-9948-424E-9AA2-C0010DF9B77CQ34994824-50CE4B31-6C17-4DDF-9348-4D2E2C52755AQ35012595-F44870F6-D120-4BBB-86E7-98931AEB4ACBQ35117565-C71399FB-0A99-4D24-A2EE-FDA494C0C2F1Q35147300-C7D229CE-D940-4BB7-8481-A0D44340C0D6Q35471348-FF57E2D3-9108-476B-BD5E-B331B158FA24Q35905838-8CC3B913-D068-42D6-987E-A934A159748AQ36410220-1F899A3F-C22C-46D4-AC64-7E1DF9C5818AQ36952282-17C9D94E-74B5-4AB0-B6E2-E9EF68604807Q37055672-9298635E-5D10-4BF9-B950-2B4D2F2DF2D1Q37177095-FADD0574-E375-413D-A85C-CB077B053273Q37232240-CD1C6DB0-FCBC-46CD-82F3-74A75BFA0BC5Q37412976-CC790EAE-7791-461C-8C32-76C25B6A11A5Q37690224-409ECABB-9CF2-47DD-B62E-EF45F792B55CQ37717423-426281B9-21CC-43E9-88FE-C8410AFC4377Q37963359-59386CEB-2E58-4712-A44B-C5988591A6E0Q38230038-3B50417A-FA34-40BF-B2DE-B9BD1D677E44Q38787286-51867A68-AEB6-4246-828B-BCC12158841CQ38818777-25735FAB-0F89-4899-B0E2-F5FCBEEBB398Q38907478-2BE58743-0C2B-479A-B7E7-9CD22E9DA930Q39097588-407C8120-538B-47F2-A15C-B9A55BF6ADDBQ39126886-D036A352-C1AC-442D-8BA0-5BADD0733366Q39964341-30761F73-DF8B-4182-97E9-F98151393CBAQ40219466-DBB78DBB-3A5A-4E87-A0BD-4741704001F3Q41640926-8DE4092A-C119-4F8D-98F7-CED6FB400C1CQ41668962-2943A11B-315C-45D0-86CF-2037510DE540Q41711062-3ADDD396-1003-4915-8E13-92740D310DB6
P2860
Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Disease-modifying effects of p ...... del of temporal lobe epilepsy.
@en
Disease-modifying effects of p ...... del of temporal lobe epilepsy.
@nl
type
label
Disease-modifying effects of p ...... del of temporal lobe epilepsy.
@en
Disease-modifying effects of p ...... del of temporal lobe epilepsy.
@nl
prefLabel
Disease-modifying effects of p ...... del of temporal lobe epilepsy.
@en
Disease-modifying effects of p ...... del of temporal lobe epilepsy.
@nl
P2093
P1476
Disease-modifying effects of p ...... del of temporal lobe epilepsy.
@en
P2093
Claudia Brandt
Maia Nozadze
Marta Rattka
Nina Heuchert
Wolfgang Löscher
P304
P356
10.1523/JNEUROSCI.0633-10.2010
P407
P577
2010-06-01T00:00:00Z